Sabado Rachel Lubong, Meseck Marcia, Bhardwaj Nina
Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Methods Mol Biol. 2016;1403:763-77. doi: 10.1007/978-1-4939-3387-7_44.
Exploitation of the patient's own immune system to induce antitumor immune responses using dendritic cell (DC) immunotherapy has been established in early clinical trials as a safe and promising therapeutic approach for cancer. However, their limited success in larger clinical trials highlights the need to optimize DC vaccine preparations. This chapter describes the methodologies utilized for the preparation of the DC vaccine most commonly used in clinical trials. Optional variations at different stages in DC vaccine preparation, based on the nature of antigen, delivery of antigen, maturation stimuli, and mode of administration for DC vaccines, are also presented for consideration as these are often dependent on the disease setting, desired immune response, and/or resources available.
利用患者自身免疫系统通过树突状细胞（DC）免疫疗法诱导抗肿瘤免疫反应，在早期临床试验中已被确立为一种安全且有前景的癌症治疗方法。然而，它们在更大规模临床试验中的有限成功凸显了优化DC疫苗制备的必要性。本章描述了用于制备临床试验中最常用的DC疫苗的方法。还介绍了基于抗原性质、抗原递送、成熟刺激以及DC疫苗给药方式在DC疫苗制备不同阶段的可选变体，以供考虑，因为这些通常取决于疾病背景、所需免疫反应和/或可用资源。
